CAS号:273404-37-8分子式:C24H33ClN4O6分子量:509纯度:≥99%(HPLC) 靶标:Caspase-1:0.8nM(Ki),Caspase-4<0.6nM(Ki) 组分 规格 VX-765 2mg 说明书 1份保存:-20℃,有效期6个月。相关搜索:VX-765(Caspase 1抑制剂),Belnacasan,VX-765,Caspase 1抑制剂,Caspase 1 Inhibitors,273404-37-8...
产品名称:IL-转化酶/caspase-1抑制剂(VX-765) 英文名称:VX-765 产品货号:M04351 产品规格:1mL(10mM)|5mg|10mg|50mg|100mg VX-765是一种的IL-转化酶/caspase-1抑制剂,抑制IL-1β释放。 注:本品仅可用于科研实验,严禁用于临床医疗及其他用途!
Taken together, these data show that the caspase-1 inhibitor VX765 upregulates Cx43 expression and improves cell-to-cell communication in rat heart after MI via suppressing the IL-1尾/p38 MAPK pathway.doi:10.1038/s41401-021-00845-8Xue-ling Su...
in the active site of caspase-1. Through its inhibitory activity, it has been demonstrated that VX-765 reduces the production of IL-1β and IL-18 in models of inflammatory disease bothin vitroandin vivo[1, 4]. In addition, it has been reported that this inhibitor blocks pyroptosis [5]...
来自中国蚌埠医学院吕合作和胡建国团队最新研究发现,选择性caspase-1抑制剂VX-765能够改善脊髓损伤局部免疫微环境,从而促进功能恢复。 免疫细胞引起的炎症是脊髓损伤的主要因素之一。因此,早期抗炎治疗对于改善脊髓损伤局部免疫微环境和提供神经保护具有非常重要的意义。目前,有关脊髓损伤抗炎药的基础和临床研究较多,但是迄今...
Belnacasan (VX-765, VX765)是VRT-043198的口服生物活性前药,一般被代谢为活性分子VRT-043198,是caspase-1选择性抑制剂,Ki值为0.8 nM。Caspase-1活化关键的炎性介质IL-1β,使其转换为有活性的分泌蛋白。Belnacasan可用于研究自身性炎症疾病,目前处于治疗银屑病和癫痫的II期临床试验中。
(2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide(VX-765),an orallyavailableselectiveinterleukin(IL)-convertingenzyme/caspase-1inhibitor,exhibitspotent anti-inflammatoryactivitiesbyinhibitingthereleaseofIL-1betaandIL-18.JPharmacolExpTher 2007,321:509-516. 3.DoitshG,GallowayNL,GengX,YangZ,Monroe...
IL-转化酶/caspase-1抑制剂(VX-765) 英文名称: VX-765 总访问: 287 国产/进口: 国产 半年访问: 32 产地/品牌: 百奥莱博 产品类别: 细胞生物学试剂 规格: 273404-37-8 最后更新: 2024-11-4 货号: M04351 CAS 号: 273404-37-8 参考报价: 立即询价 电话咨询 ...
RESULTS: VX-765 reduced infarct size (28 vs 48% control; P<0.05) to a similar extent as IPC (30%; P<0.05). The PI3 kinase inhibitor, wortmannin, abolished the protective effect of VX-765. Importantly in the model used, we were unable to show additive protection with VX-765 + IPC....
Here, we show that the nontoxic and blood-brain barrier permeable small molecule Caspase-1 inhibitor VX-765 dose-dependently reverses episodic and spatial memory impairment, and hyperactivity in the J20 mouse model of AD. Cessation of VX-765 results in the reappearance of memory deficits in the ...